Abstract
BackgroundThe safety of newer non anti-TNF biologic agents [abatacept (ABA), tocilizumab (TCZ) and rituximab (RTX)] in patients with autoimmune rheumatic diseases and past HBV infection [defined as HBsAg(−), anti-HBc(+), anti-HBs(±)]...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have